Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 8,739 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Heart Disease Clear all
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways

NCT07775976
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities, His-Purkinje Disease, Arrhythmias, Cardiac, Rhythm Phenotypes, Myocardial Ischemia, Syncope, Syncope Recurrent, Syncope and Collapse, Seizure Disorder, Sleep Apnea Syndrome, Obstructive, Decision Support Systems, Clinical, Heart Failure - NYHA II - IV, Heart Failure (for Example, Fluid Overload), HRV, Cardiopulmonary, Sudden Cardiac Arrest, Cardiac Arrest (CA), Ventricular Arrhythmias and Cardiac Arrest, Ventricular Fibrillation, QT Dispersion, Atrial Cardiomyopathy
Interventions
COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
Device · Other
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Pasadena, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 20, 2026, 5:31 AM EDT
Recruiting Phase 4 Interventional

LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions

NCT05786417
View directory record Official record
Conditions
Angina, Stable Ischemic Heart Disease
Interventions
Clinician Discretion, Beta blocker, Calcium channel blocker
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
65 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
New Haven, Connecticut • Marietta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Not applicable Interventional Results available

Randomized Evaluation of Redo Ablation Procedures of Atrial Fibrillation With FIRM Guided Procedures

NCT02799043
View directory record Official record
Conditions
Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation
Interventions
Standard PVI, FIRM-Guided Procedure and PVI
Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 80 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
Phoenix, Arizona • Ventura, California • Fort Lauderdale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography

NCT01683825
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
F-18 florbetapir PET
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Not applicable Interventional Results available

Reducing Hopelessness Through Improved Physical Activity in Adults With Heart Disease: With COVID-19 Considerations

NCT03907891
View directory record Official record
Conditions
Ischemic Heart Disease, Hopelessness, Physical Activity, Motivation, Social Support, Covid19
Interventions
Motivational social support from nurse, Motivational social support from nurse with additional support from significant other, Attention control
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)

NCT00095238
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Irbesartan, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
60 Years and older
Enrollment
4,128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
60
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

NCT01442038
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
2,651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
86
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 20, 2026, 5:31 AM EDT
Withdrawn Not applicable Interventional

Beta-blocker Before Extubation

NCT00563238
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Metoprolol
Drug
Lead sponsor
Gregory A. Schmidt
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 20, 2026, 5:31 AM EDT
Not listed Phase 1Phase 2 Interventional

Acupuncture for the Treatment of Medication-Dependent Hypotension in Heart Failure

NCT04952935
View directory record Official record
Conditions
Congestive Heart Failure, Hypotension
Interventions
True Acupuncture, Sham Acupuncture
Procedure
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 20, 2026, 5:31 AM EDT
Completed No phase listed Observational

Implantable Loop Recorders in Post-atrial Fibrillation (AF) Ablation: RPAF-A

NCT01061125
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
TTM and Holter monitor
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 20, 2026, 5:31 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.

NCT03428048
View directory record Official record
Conditions
Coronary Artery Disease, Atrial Fibrillation (AF)
Interventions
Hybrid procedure, Endocardial ablations, left atrial appendage occlusion
Procedure
Lead sponsor
Cardiovascular Innovation and Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
1
States / cities
Glenwood Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Not applicable Interventional Results available

Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery

NCT00791648
View directory record Official record
Conditions
Acute Kidney Injury, Post-Operative Delirium, Icu Delirium, Acute Renal Failure, Delirium
Interventions
atorvastatin, placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 20, 2026, 5:31 AM EDT
Terminated Not applicable Interventional

ATS 3f(r) Aortic Bioprosthesis Model 1000, 19mm

NCT00657826
View directory record Official record
Conditions
Heart Valve Diseases
Interventions
ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 20, 2026, 5:31 AM EDT
Recruiting Phase 4 Interventional

Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure

NCT06979726
View directory record Official record
Conditions
Heart Failure, Volume Overload
Interventions
Lasix ONYU
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 20, 2026, 5:31 AM EDT
Recruiting No phase listed Observational

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

NCT07358078
View directory record Official record
Conditions
Transthyretin Amyloidosis With Cardiomyopathy
Interventions
Not listed
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
13
States / cities
Tucson, Arizona • Beverly Hills, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 3 Interventional

Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.

NCT00048425
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Levosimendan
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
132
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2006 · Synced Oct 20, 2026, 5:31 AM EDT
Active, not recruiting Not applicable Interventional

Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction

NCT03533517
View directory record Official record
Conditions
Heart Failure, Cardiomyopathy, Dilated
Interventions
AccuCinch® Ventricular Restoration
Device
Lead sponsor
Ancora Heart, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
18
States / cities
San Francisco, California • Atlanta, Georgia • Louisville, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Not applicable Interventional

Clinician Counseling and Cultural Competency to Improve Hypertension Control and Therapy Adherence

NCT00201149
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension
Interventions
Patient-centered Counseling
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 100 Years
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 20, 2026, 5:31 AM EDT
Not listed No phase listed Observational

TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)

NCT00985049
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 20, 2026, 5:31 AM EDT
Active, not recruiting No phase listed Observational

An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.

NCT07062848
View directory record Official record
Conditions
Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions
AI Toolkit for ATTR-CM Diagnosis
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
50 Years to 95 Years
Enrollment
1,500,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

NCT01877915
View directory record Official record
Conditions
Heart Failure, Coronary Artery Disease
Interventions
Rivaroxaban, Placebo, Standard of care for heart failure and coronary artery disease
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 95 Years
Enrollment
5,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
115
States / cities
Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 112 more
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 20, 2026, 5:31 AM EDT
Terminated Not applicable Interventional

Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation

NCT06364215
View directory record Official record
Conditions
Atrial Fibrillation Paroxysmal
Interventions
Farapulse PFA, Pulmonary Vein Isolation alone, Farapulse PFA, Pulmonary Vein Isolation and Left atrial Posterior Wall Isolation
Device
Lead sponsor
Jorge Romero
Other
Eligibility
21 Years to 90 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging

NCT02115308
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson
Drug
Lead sponsor
Timothy M. Bateman
Other
Eligibility
19 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 20, 2026, 5:31 AM EDT